[go: up one dir, main page]

WO2022085710A1 - Agent d'inactivation de coronavirus - Google Patents

Agent d'inactivation de coronavirus Download PDF

Info

Publication number
WO2022085710A1
WO2022085710A1 PCT/JP2021/038711 JP2021038711W WO2022085710A1 WO 2022085710 A1 WO2022085710 A1 WO 2022085710A1 JP 2021038711 W JP2021038711 W JP 2021038711W WO 2022085710 A1 WO2022085710 A1 WO 2022085710A1
Authority
WO
WIPO (PCT)
Prior art keywords
ppm
less
alkyl ether
polyoxyethylene alkyl
ethylene oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/038711
Other languages
English (en)
Japanese (ja)
Inventor
悠記 石田
勢造 八城
拓也 森本
和彦 片山
慧 芳賀
玲子 戸高
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Kitasato Institute
Original Assignee
Kao Corp
Kitasato Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp, Kitasato Institute filed Critical Kao Corp
Publication of WO2022085710A1 publication Critical patent/WO2022085710A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/30—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
    • A01N31/02—Acyclic compounds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
    • A01N31/04—Oxygen or sulfur attached to an aliphatic side-chain of a carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N61/00—Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Definitions

  • the present invention relates to a SARS coronavirus-2 inactivating agent.
  • SARS coronavirus-2 (Severe acute respiratory syndrome 2,; SARS-CoV-2) belongs to the genus Beta coronavirus like SARS coronavirus (SARS-CoV) and MERS coronavirus (MERS-CoV), and acute respiration. It is a SARS-related coronavirus that causes organ disease (COVID-19). SARS-CoV-2 was first confirmed to occur near Wuhan City, Hubei City, China in 2019, and has since caused a pandemic of COVID-19.
  • ethanol and surface activity are used to prevent infection by inactivating the virus by cleaning and disinfecting hands, fingers, clothing, and various appliances / members that may have the virus attached.
  • disinfectants such as agents and hypochlorite water for SARS-CoV-2 has been evaluated.
  • Non-Patent Document 1 "The final report on the effectiveness evaluation of the disinfection method for the new coronavirus has been compiled.-It can be used for disinfection of articles-", [online], [Reiwa 2nd September 18th Search], Internet ⁇ URL: https: // www. nite. go. jp / information / osirase20200626. html>
  • the present invention relates to the following 1) to 20).
  • SARS coronavirus-2 inactivating agent having a concentration of the polyoxyethylene alkyl ether of 150 ppm or more and less than 2000 ppm.
  • SARS coronavirus-2 inactivating agent having a concentration of 100 ppm or more and less than 2000 ppm of the polyoxyethylene alkyl ether.
  • a preventive agent for SARS coronavirus-2 infection containing polyoxyethylene alkyl ether having 12 carbon atoms and an average ethylene oxide molar addition of 8 or less as an active ingredient.
  • the concentration of the polyoxyethylene alkyl ether is 100 ppm or more and less than 2000 ppm.
  • the polyoxyethylene alkyl ether has a concentration of 100 ppm or more and less than 2000 ppm, and is used. 9) A polyoxyethylene alkyl ether having a concentration of 150 ppm or more and less than 2000 ppm having 12 carbon atoms and an average ethylene oxide molar addition of 8 or less for use in SARS coronavirus-2 inactivation. 10) Polyoxyethylene having a concentration of 100 ppm or more and less than 2000 ppm having 12 carbon atoms and an average ethylene oxide addition molar number of 1, 3 to 6 or 8 for use in SARS coronavirus-2 inactivation. Alkyl ether.
  • the polyoxyethylene alkyl ether has a concentration of 100 ppm or more and less than 2000 ppm, and is used.
  • SARS coronavirus applied to a polyoxyethylene alkyl ether having 12 carbon atoms and an average ethylene oxide molar addition of 8 or less in an alkyl group having a concentration of 150 ppm or more and less than 2000 ppm and requiring it. 2 inactivation methods.
  • a polyoxyethylene alkyl ether having 12 carbon atoms and an average ethylene oxide molar addition of 1, 3 to 6 or 8 is applied to an object having a concentration of 100 ppm or more and less than 2000 ppm and requiring it.
  • SARS coronavirus-2 inactivation method is applied to a polyoxyethylene alkyl ether having 12 carbon atoms and an average ethylene oxide molar addition of 1, 3 to 6 or 8 is applied to an object having a concentration of 100 ppm or more and less than 2000 ppm and requiring it.
  • SARS coronavirus applied to a polyoxyethylene alkyl ether having 12 carbon atoms and an average ethylene oxide molar addition of 8 or less in an alkyl group having a concentration of 150 ppm or more and less than 2000 ppm and requiring it. 2 How to prevent infectious diseases.
  • a polyoxyethylene alkyl ether having 12 carbon atoms and an average ethylene oxide molar addition of 1, 3 to 6 or 8 is applied to an object having a concentration of 100 ppm or more and less than 2000 ppm and requiring it. How to prevent SARS coronavirus-2 infection.
  • the present invention relates to providing a SARS-CoV-2 inactivating agent that exhibits an excellent SARS-CoV-2 inactivating effect.
  • SARS-CoV-2 can be inactivated even when used at a low concentration of a surfactant, and the spread of SARS-CoV-2 infection can be prevented or reduced.
  • a polyoxyethylene alkyl ether having 12 carbon atoms and an average ethylene oxide molar addition (EO) of 8 or less is used as an active ingredient for SARS coronavirus-2 inactivation. ..
  • EO ethylene oxide molar addition
  • a polyoxyethylene alkyl ether having 12 carbon atoms and an average ethylene oxide molar addition of 8 or less may be simply referred to as “polyoxyethylene alkyl ether”.
  • the polyoxyethylene alkyl ether used in the present invention has an alkyl group having 12 carbon atoms and an average ethylene oxide molar addition of 8 or less.
  • the polyoxyethylene alkyl ether may be used alone or in combination of two or more.
  • Polyoxyethylene alkyl ethers are commercially available. Further, it may be chemically synthesized by a conventional method.
  • the average number of moles of ethylene oxide added to the polyoxyethylene alkyl ether is 8 or less, but from the viewpoint of SARS-CoV-2 inactivation, it is preferably 1 or more, more preferably 2 or more, still more preferably 3 or more, and also. , It is preferably 8 or less, and more preferably 6 or less.
  • the average number of moles of ethylene oxide added to the polyoxyethylene alkyl ether is preferably 1 to 8, more preferably 2 to 8, and even more preferably 3 to 6.
  • the polyoxyethylene alkyl ether may be purified to a high degree of purity or may have a distribution in the number of moles of ethylene oxide added, but from the viewpoint of SARS-CoV-2 inactivation, the number of moles of ethylene oxide added may be used. Those with a distribution are preferable. From the same viewpoint, the polyoxyethylene alkyl ether preferably contains 30% by mass or more, more preferably 50% by mass or more, of low-addition molars having an addition molar number of ethylene oxide of 1 to 6 in total. Further, the upper limit of the total amount of low-addition molars having an addition molar number of ethylene oxide of 1 to 6 is not particularly limited, but is preferably 70% by mass or less.
  • the number of moles of ethylene oxide added can be analyzed by gas chromatography analysis.
  • Gas chromatography measurement conditions Measuring equipment: Agent6850 Column: 100% dimethylpolysiloxane non-polar capillary column 15m Carrier gas: Helium INJ Temperature: 300 ° C DET temperature: 350 ° C Column temperature: 60 ° C to 350 ° C Detector: FID Injection volume: 1 ⁇ l
  • the concentration of the polyoxyethylene alkyl ether is 150 ppm (mass ppm, the same applies hereinafter) or more, preferably 250 ppm or more, more preferably 270 ppm or more, still more preferably, from the viewpoint of SARS-CoV-2 inactivation.
  • Is 300 ppm or more and is less than 2000 ppm, preferably 1500 ppm or less, more preferably 1000 ppm or less, still more preferably 500 ppm or less, from the viewpoint of cost and damage to the inactivated target.
  • the concentration of the polyoxyethylene alkyl ether is 150 ppm or more and less than 2000 ppm, preferably 250 ppm or more and less than 2000 ppm, more preferably 250 ppm or more and 1500 ppm or less, more preferably 270 ppm or more and 1500 ppm or less, and further preferably 270 ppm. It is 1000 ppm or more, and more preferably 300 ppm or more and 500 ppm or less.
  • a polyoxyethylene alkyl ether having 12 carbon atoms and an average ethylene oxide molar addition of 1, 3 to 6 or 8 has a SARS-CoV-2 inactivating effect at a lower concentration of 100 ppm. Admitted. Therefore, the concentration of the polyoxyethylene alkyl ether having 12 carbon atoms and an average ethylene oxide molar addition of 1, 3 to 6 or 8 is 100 ppm or more from the viewpoint of SARS-CoV-2 inactivation.
  • the concentration of the polyoxyethylene alkyl ether having 12 carbon atoms and an average ethylene oxide molar addition of 1, 3 to 6 or 8 is 100 ppm or more and less than 2000 ppm, preferably 150 ppm or more and less than 2000 ppm.
  • SARS-CoV-2 is a SARS-related coronavirus that causes acute respiratory disease (COVID-19).
  • SARS-CoV-2 has a viral genome of about 29,903 bases and is a single-strand plus-strand RNA virus.
  • the virus particles (virions) have a size of about 50 to 200 nm.
  • coronavirus Like a common coronavirus, it is composed of four proteins known as spike proteins, nucleoproteins, endogenous membrane proteins, and enveloped proteins, and RNA. Of these, nucleocapsids bind to RNA to form nucleocapsids, and lipid-bound spike proteins, endogenous membrane proteins, and envelope proteins surround them to form envelopes (A pneumonia outbreak assisted with a new coronavirus of prob). bat orange. Nature. 2020 Mar; 579 (7778): 270-273., A new coronavirus associated with human respiratory dissease in China. Nature. 2020.
  • Peplomers are large transmembrane proteins of type I consisting of two subunits, S1 and S2, where S1 is primarily a receptor binding domain (RBD) that recognizes cell surface receptors and S2 is a membrane fusion. Contains the necessary elements.
  • ACE2 angiotensin converting enzyme 2
  • DPP4 dipeptidyl peptidase-4
  • APN aminopeptidase N
  • CEACAM cancer fetal antigen-related cell adhesion molecule 1
  • O- There is ac Sia O-acetylated sialic acid
  • SARS-CoV-2 Spike Glycoprotein Cell. Volume 1811, Issue 2, 16 April 2020, Pages 281-292.e6).
  • the anti-SARS-CoV-2 verification test in the present specification is performed by a system in which SARS-CoV-2 treated with an inactivating agent to be evaluated is infected with Vero C1008 or E6 / TMPRSS2 cells. Details will be described later.
  • the verification test the case where the inoculated virus is almost completely inactivated (to the detection limit or less) is regarded as having an inactivating effect.
  • a polyoxyethylene alkyl ether having 12 carbon atoms and an average ethylene oxide molar addition of 8 or less has a SARS-CoV-2 inactivating effect, and thus becomes a SARS-CoV-2 inactivating agent. Obtained and can be used for SARS-CoV-2 inactivation. It can also be used to produce the SARS-CoV-2 inactivating agent. SARS-CoV-2 inactivation can prevent the virus infection and prevent or ameliorate the SARS-COV-2 infection.
  • "use” may be therapeutic or non-therapeutic use when it is used in a living body (human or non-human animal).
  • Non-therapeutic is a concept that does not include medical practice, that is, a concept that does not include a method of surgery, treatment or diagnosis of humans, more specifically, surgery on humans by a doctor or a person who has been instructed by a doctor. , A concept that does not include a method of performing treatment or diagnosis.
  • SARS-COV-2 infection refers to an acute respiratory disease (COVID-19) caused by infection with SARS-COV-2.
  • the symptoms are not specific and range from asymptomatic to severe pneumonia. Typical symptoms / signs include fever, dry cough, fatigue, sputum, shortness of breath, sore throat, headache, diarrhea, olfactory abnormality, etc., but the present invention is not limited to such symptoms.
  • prevention means preventing, suppressing or delaying SARS-COV-2 infection in an individual, or reducing the risk of developing SARS-COV-2 infection.
  • “Improvement” means infection of SARS-COV-2 or improvement of symptoms, prevention or delay of exacerbation of symptoms, or reversal, prevention or delay of progression of symptoms, and is intended to include "treatment”.
  • the SARS-CoV-2 inactivating agent of the present invention may be in the form of using a polyoxyethylene alkyl ether having 12 carbon atoms of an alkyl group and an average ethylene oxide molar addition of 8 or less alone, or may be used alone. , Depending on the mode of use, it may be in the form of a composition containing these and other components such as a solvent and a pharmaceutical additive as appropriate.
  • the composition may be in an undiluted form or in a diluted form. The undiluted form is used for SARS-CoV-2 inactivation to be treated without being diluted.
  • the concentration after dilution with the recommended dilution concentration is that the polyoxyethylene alkyl ether having 12 carbon atoms of the alkyl group and 8 or less the average number of moles of ethylene oxide added has the effect of inactivating SARS-CoV-2. It is diluted with a suitable medium such as water so as to have the above-mentioned active ingredient concentration to be exhibited, and is used for SARS-CoV-2 inactivation to be treated.
  • the SARS-CoV-2 inactivating agent cleans hands and fingers, foods such as vegetables and fish, hard surfaces of inanimate objects, fibers and textile products where contamination of SARS-CoV-2 is a concern; It becomes a product or formulation used for air purification, etc., or is used as a material for SARS-CoV-2 inactivation in the product or formulation.
  • Hard surfaces include floors, walls, windows, doors, food processing equipment, medical equipment, dressing rooms and toilets, bathrooms, washrooms, shower stands, kitchens, living rooms, etc.
  • Various furniture such as bedrooms, home appliances, appliances, tools, etc. can be mentioned.
  • Examples of the material of the hard surface include plastic (including silicone resin and the like), metal, pottery, wood, glass, or a combination thereof.
  • textiles and textile products include clothing, towels, masks, sofas, cushions, bedding, curtains, shoes, bags and the like.
  • the SARS-CoV-2 inactivating agent of the present invention may be brought into contact with the treatment target.
  • the contact time is 10 seconds or more, preferably 1 minute or more, more preferably 10 minutes or more from the viewpoint of SARS-CoV-2 inactivation, and 24 hours or less, preferably 1 hour or less, from the viewpoint of workload. More preferably, it is 30 minutes or less.
  • the means of contact is not particularly limited, and examples thereof include coating or spraying, dipping, washing, adding, and volatilizing.
  • the form of the product or the pharmaceutical product can be appropriately selected depending on the intended use, and may be, for example, liquid, gel-like, paste-like, or solid-like. Further, the number of carbon atoms of the alkyl group is 12 and the average number of moles of ethylene oxide added to the woven fabric or non-woven fabric of paper, natural fiber, recycled fiber (rayon, etc.) and / or synthetic fiber (polyethylene, polypropylene, polyester, etc.) is 8 or less. It can be in the form of being coated or impregnated with the polyoxyethylene alkyl ether.
  • Specific forms of products and formulations include, for example, skin cleaners such as hand soaps, kitchen detergents, laundry detergents, softeners, household detergents, toilet cleaners, bath cleaners, and contact lens cleaners / preservatives. , Paper products, wet wipes, space spray products, air purifiers, humidifiers, dehumidifiers, filters for air conditioners and air purifiers, etc.
  • the above-mentioned products and formulations can be prepared according to a conventional method by appropriately combining the above-mentioned active ingredient of the present invention or other ingredients other than the above-mentioned active ingredient within a range that does not impair the effect of the present invention.
  • Such other components include, for example, chelating agents, water-soluble solvents, oils, higher fatty acids, silicones, alkaline agents, pH regulators, water softeners, metal sequestering agents, dispersants, stabilizers, enzymes, fluorescent compounds. Examples thereof include whitening agents, bleaching agents, moisturizing agents, thickening agents, suspending agents, preservatives, antibacterial agents, defoaming agents, powder components, pigments, fluorescent dyes, fragrances, and other surfactants.
  • surfactants include ionic surfactants (anionic surfactants, cationic surfactants, etc.) other than polyoxyethylene alkyl ethers having an alkyl group having 12 carbon atoms and an average ethylene oxide molar addition of 8 or less. Amphoteric surfactants), nonionic surfactants, polymer surfactants and the like.
  • the content of the active ingredient of the present invention in the SARS-CoV-2 inactivating agent of the present invention can be appropriately determined according to the form of the composition.
  • the preferable content in products and preparations assuming dilution is more preferably 150 ppm or more and 20% by mass or less for polyoxyethylene alkyl ether having 12 carbon atoms of the alkyl group and 8 or less average number of moles of ethylene oxide added.
  • the polyoxyethylene alkyl ether is 250 ppm or more and 20% by mass or less, and more preferably the polyoxyethylene alkyl ether is 270 ppm or more and 10% by mass or less.
  • the preferable content in products and formulations that are not expected to be diluted is more preferably 150 ppm or more and 20% by mass or less for polyoxyethylene alkyl ether having 12 carbon atoms in the alkyl group and 8 or less in the average number of moles of ethylene oxide added.
  • the polyoxyethylene alkyl ether is 250 ppm or more and 20% by mass or less, and more preferably the polyoxyethylene alkyl ether is 300 ppm or more and 10% by mass or less.
  • the present invention further discloses the following aspects.
  • SARS coronavirus-2 inactivating agent having a concentration of the polyoxyethylene alkyl ether of 150 ppm or more and less than 2000 ppm.
  • SARS coronavirus-2 inactivating agent having a concentration of 100 ppm or more and less than 2000 ppm of the polyoxyethylene alkyl ether.
  • a preventive agent for SARS coronavirus-2 infection in which the concentration of the polyoxyethylene alkyl ether is 100 ppm or more and less than 2000 ppm.
  • ⁇ 5> The use of a polyoxyethylene alkyl ether having 12 carbon atoms and an average ethylene oxide addition molar number of 8 or less in an alkyl group for producing a SARS coronavirus-2 inactivating agent, wherein the polyoxyethylene is used. Used, where the concentration of alkyl ether is 150 ppm or more and less than 2000 ppm.
  • ⁇ 6> The use of a polyoxyethylene alkyl ether having 12 carbon atoms and an average ethylene oxide addition molar number of 1, 3 to 6 or 8 for producing a SARS coronavirus-2 inactivating agent. , The concentration of the polyoxyethylene alkyl ether is 100 ppm or more and less than 2000 ppm, used.
  • a polyoxyethylene alkyl ether having 12 carbon atoms and an average ethylene oxide addition molar number of 8 or less in an alkyl group for producing a preventive agent for SARS coronavirus-2 infection wherein the polyoxyethylene alkyl ether is used. Used, where the concentration of oxyethylene alkyl ether is 150 ppm or more and less than 2000 ppm.
  • the polyoxyethylene alkyl ether has a concentration of 100 ppm or more and less than 2000 ppm, and is used.
  • Polyoxyethylene alkyl ether having a concentration of 150 ppm or more and less than 2000 ppm having 12 carbon atoms and an average ethylene oxide molar addition of 8 or less for use in the prevention of SARS coronavirus-2 infection. .. ⁇ 12> The alkyl group having a concentration of 100 ppm or more and less than 2000 ppm has 12 carbon atoms and an average ethylene oxide molar addition of 1, 3 to 6 or 8 for use in the prevention of SARS coronavirus-2 infection. Polyoxyethylene alkyl ether.
  • the polyoxyethylene alkyl ether has a concentration of 100 ppm or more and less than 2000 ppm, and is used.
  • ⁇ 16> With non-therapeutic use of polyoxyethylene alkyl ether having 12 carbon atoms and an average ethylene oxide molar addition of 1, 3 to 6 or 8 to prevent SARS coronavirus-2 infection.
  • the polyoxyethylene alkyl ether has a concentration of 100 ppm or more and less than 2000 ppm, and is used.
  • SARS coronavirus applied to a polyoxyethylene alkyl ether having 12 carbon atoms and an average ethylene oxide molar addition of 8 or less in an alkyl group having a concentration of 150 ppm or more and less than 2000 ppm and requiring it.
  • -2 inactivation method ⁇ 18> Polyoxyethylene alkyl ethers having 12 carbon atoms and an average ethylene oxide molar addition of 1, 3 to 6 or 8 in an alkyl group having a concentration of 100 ppm or more and less than 2000 ppm and requiring it.
  • SARS coronavirus applied to a polyoxyethylene alkyl ether having 12 carbon atoms and an average ethylene oxide molar addition of 8 or less in an alkyl group having a concentration of 150 ppm or more and less than 2000 ppm and requiring it.
  • -2 How to prevent infectious diseases.
  • Applicable SARS coronavirus-2 infection prevention method Applicable SARS coronavirus-2 infection prevention method.
  • the average number of moles of ethylene oxide added to the polyoxyethylene alkyl ether is preferably 1 or more, more preferably 2 or more, still more preferably 3 or more, and preferably 8 or more. It is less than or equal to, more preferably 6 or less, preferably 1 to 8, more preferably 2 to 8, and even more preferably 3 to 6.
  • the polyoxyethylene alkyl ether is a total of low-added molars having 1 to 6 added moles of ethylene oxide, preferably 30% by mass or more, more preferably 50% by mass. % Or more, preferably 70% by mass or less.
  • the concentration of the polyoxyethylene alkyl ether is 150 ppm or more, preferably 250 ppm or more, more preferably 270 ppm or more, still more preferably 300 ppm or more. Further, it is less than 2000 ppm, preferably 1500 ppm or less, more preferably 1000 ppm or less, further preferably 500 ppm or less, and 150 ppm or more and less than 2000 ppm, preferably 250 ppm or more and less than 2000 ppm.
  • the number of carbon atoms of the alkyl group is The concentration of the polyoxyethylene alkyl ether in which the average number of moles of ethylene oxide added is 1, 3 to 6 or 8 is 100 ppm or more, preferably 150 ppm or more, more preferably 200 ppm or more, still more preferably 250 ppm or more.
  • the target is preferably a hand or finger, a food, a hard surface of an inanimate object, a fiber or a textile product, or air, which may be contaminated with SARS-CoV-2. ..
  • Polyoxyethylene (1EO) lauryl ether The total amount of low-addition molars having an average number of moles of ethylene oxide added of 1 and ethylene oxide of 1 to 6 is 48.5% by mass and 99% by mass of the active ingredient.
  • -Polyoxyethylene (2EO) lauryl ether Total amount of low-addition molars with ethylene oxide average addition moles 2 and ethylene oxide addition moles 1 to 6 63.3% by mass, active ingredient 99% by mass % Or more Polyoxyethylene (1EO) lauryl ether and polyoxyethylene (2EO) lauryl ether are added and polymerized with lauryl alcohol (purity 98% by mass or more) under high temperature and pressure. Synthesized. KOH was used as the catalyst for the synthesis, and acetic acid was used for the neutralization.
  • Polyoxyethylene (3EO) lauryl ether Emalgen 103, ethylene oxide average number of moles of addition 3, total amount of low-addition moles of ethylene oxide of 1 to 6 is 68.8% by mass, Kao ( Made by Co., Ltd., active ingredient 99% by mass or more ⁇ Polyoxyethylene (4EO) lauryl ether: Emulgen 105, ethylene oxide average addition mole number 4, ethylene oxide addition mole number 1 to 6 low addition mole body Total amount 66.2% by mass, manufactured by Kao Co., Ltd., active ingredient 99% by mass or more-Polyoxyethylene (5EO) lauryl ether: Emargen 106, average number of moles of ethylene oxide added 5, number of moles of ethylene oxide added 60.0% by mass of low-addition molars of 1 to 6, manufactured by Kao Co., Ltd., 99% by mass or more of active ingredient ⁇ Polyoxyethylene (6EO) lauryl ether: Emargen 108, average addition of ethylene oxide Total amount of 50.0%
  • SARS-CoV-2 inactivation was judged by viral cytopathic effect and RT-qPCR. No viral cytopathic effect was observed by microscopic observation using IX73 (Olympus), and RT-qPCR of the culture supernatant showed When the viral genome could not be detected, it was determined that SARS-CoV-2 was inactivated. In RT-qPCR, it was judged that the virus had propagated when the Ct (Threshold Cycle) value was less than 30.
  • SARS-CoV-2 JPN / TY / WK-521
  • Cell Vero C1008 (ATCC CRL-1586)
  • Medium 500 mL MEM (Sigma-Aldrich, M4655) 5 mL Penicillin-Streptomycin (10,000 U / mL) (Gibco, 15140122)
  • FBS biosera, FB-1365 / 500, Lot10259 Deactivated 56 ° C., 30 minutes
  • Addition to 10% medium during normal culture Addition to 2% medium during infection
  • Trypsin TrypsLE® Select Enzyme (1X), no phenol red (Gibco, 12563011)
  • RT-qPCR SARS-CoV-2 Detection Kit-N2 set- (Toyobo, NCV-302) (protocol) 1.
  • the SARS-CoV-2 inactivating effect was confirmed at a low concentration in the polyoxyethylene alkyl ether having 12 carbon atoms and an average ethylene oxide molar addition molar number of 8 or less.
  • a SARS-CoV-2 inactivating effect was confirmed at a lower concentration of 100 ppm.
  • a polyoxyethylene alkyl ether having 12 carbon atoms and an average ethylene oxide molar addition of 9 or 10 and an alkyl group having 16 carbon atoms and an average ethylene oxide molar addition of 4 or 5 are used.
  • a SARS-CoV-2 inactivating effect was not observed in a certain polyoxyethylene alkyl ether, a polyoxyethylene alkyl ether having an alkyl group having 18 carbon atoms and an average ethylene oxide molar addition of 4.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Dentistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Agronomy & Crop Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un agent d'inactivation du SARS-CoV-2 présentant un excellent effet d'inactivation du SARS-CoV-2.　L'agent d'inactivation du SARS-CoV-2 contient, en tant que principe actif, un éther alkylique de polyoxyéthylène dans lequel le nombre d'atomes de carbone dans un groupe alkyle est de 12 et dans lequel le nombre ajouté moyen de moles d'oxydes d'éthylène est inférieur ou égal à 8. La concentration de l'éther alkylique de polyoxyéthylène n'est pas inférieure à 150 ppm mais inférieure à 2000 ppm.
PCT/JP2021/038711 2020-10-20 2021-10-20 Agent d'inactivation de coronavirus Ceased WO2022085710A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-176210 2020-10-20
JP2020176210 2020-10-20

Publications (1)

Publication Number Publication Date
WO2022085710A1 true WO2022085710A1 (fr) 2022-04-28

Family

ID=81290606

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/038711 Ceased WO2022085710A1 (fr) 2020-10-20 2021-10-20 Agent d'inactivation de coronavirus

Country Status (3)

Country Link
JP (1) JP2022067656A (fr)
TW (1) TW202223086A (fr)
WO (1) WO2022085710A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024101249A1 (fr) 2022-11-07 2024-05-16 日環科学株式会社 Inhibiteur d'infection virale
JP2024075507A (ja) * 2022-11-22 2024-06-03 株式会社ニイタカ 抗ウイルスコーティング剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011095764A2 (fr) * 2010-01-02 2011-08-11 Intelligent Therapeutics Limited Composés antimicrobiens
JP6795720B1 (ja) * 2020-07-08 2020-12-02 花王株式会社 コロナウイルス不活化剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011095764A2 (fr) * 2010-01-02 2011-08-11 Intelligent Therapeutics Limited Composés antimicrobiens
JP6795720B1 (ja) * 2020-07-08 2020-12-02 花王株式会社 コロナウイルス不活化剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KEBBI SARA, NOMAN LABIB, DEMIRTAS IBRAHIM, BENSOUICI CHAWKI, ADEM SEVKI, BENAYACHE SAMIR, BENAYACHE FADILA, SEGHIRI RAMDANE, GOK M: "In vitro Antioxidant and Anticholinesterase Activities of Senecio massaicus Essential Oil and Its Molecular Docking Studies as a Potential Inhibitor of Covid-19 and Alzheimer’s Diseases", JOURNAL OF BIOLOGICALLY ACTIVE PRODUCTS FROM NATURE, vol. 11, no. 4, 4 July 2021 (2021-07-04), pages 380 - 394, XP055923528, ISSN: 2231-1866, DOI: 10.1080/22311866.2021.1955006 *
NITE: "Efficacy evaluation of alternative disinfection method for new coronavirus ( final report ) ", MINISTRY OF ECONOMY, TRADE AND INDUSTRY, 26 June 2020 (2020-06-26), XP055923499, Retrieved from the Internet <URL:https://www.nite.go.jp/data/000111315.pdf> [retrieved on 20220520] *
TABATA YUJIN, MURATA TOMOJI: "Physico-chemical Properties of Homogeneous Nonionic Surfactants", JOURNAL OF JAPAN OIL CHEMISTS' SOCIETY, vol. 33, no. 7, 20 July 1984 (1984-07-20), pages 443 - 446, XP055923509, DOI: 10.5650/jos1956.33.443 *

Also Published As

Publication number Publication date
JP2022067656A (ja) 2022-05-06
TW202223086A (zh) 2022-06-16

Similar Documents

Publication Publication Date Title
JP2013040167A (ja) 抗ウイルス剤組成物
WO2022085710A1 (fr) Agent d&#39;inactivation de coronavirus
JP6990285B1 (ja) コロナウイルス不活化剤
JP7421902B2 (ja) ウイルス不活性化剤組成物
JP7421904B2 (ja) ウイルス不活性化剤組成物
JP2022026762A (ja) ウイルス不活性化剤組成物
JP2019210266A (ja) 殺菌・ウイルス不活化剤及び殺菌・ウイルス不活化方法
WO2022009352A1 (fr) Agent d&#39;inactivation du coronavirus
US20240165138A1 (en) Antiviral agent
WO2022244531A1 (fr) Détergent neutre anti-virus enveloppé, composition désinfectante et procédé d&#39;inactivation de virus enveloppés
JP7421903B2 (ja) ウイルス不活性化剤組成物
JPH01272503A (ja) 手指殺菌消毒用洗浄剤
JP7340290B2 (ja) 抗エンベロープウイルス中性洗浄剤、消毒剤組成物、及びエンベロープウイルスの不活性化方法
JP7534729B2 (ja) Ｓａｒｓコロナウイルス２不活性化剤
JP2022029409A (ja) 抗ウイルス組成物
JP2024044307A (ja) 液体ウイルス不活化組成物
JP7701965B1 (ja) 液体洗浄剤組成物
JP6973835B1 (ja) 抗ウイルス剤
JP2023070880A (ja) エンベロープウイルス不活性化剤
US20240189210A1 (en) Use of a cationic polymer for reinfection prevention
JP2025112878A (ja) ウイルス不活化剤
EP4473834A1 (fr) Procédé d&#39;inactivation de virus ou de bactérie
JP2023063142A (ja) ウイルス不活化剤
JP2023063212A (ja) ウイルス不活化剤
JP2024031837A (ja) ウイルス不活化剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21882851

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21882851

Country of ref document: EP

Kind code of ref document: A1